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Randomized Global Double-Blind Phase II Study Evaluating
MetMAb in Combination with Erlotinib, in Patients with Ad-
vanced Non-Small-Cell Lung Cancer
D. R. Spigel1,2, T. J. Ervin1,3, R. Ramlau4, D. Daniel1,5, J. Goldschmidt6, M.
Krzakowski7, B. Godbert8, R. Yauch9, P. H. Patel9, A. Peterson9, 1Sarah
Cannon Research Institute, Nashville, TN, 2Tennessee Oncology, PLLC,
Nashville, TN, 3Florida Cancer Specialists, Fort Myers, FL, 4Wielkopolskie
Centrum Pulmonologii i Torakochirurgii, Poznan˜, Poland, 5Chattanooga
Oncology and Hematology Associates, Chattanooga, TN, 6Blue Ridge Can-
cer Care, Salem, VA, 7Centrum Onkologii, Warsaw, Poland, 8Hoˆpitaux de
Brabois, Nancy, France, 9Genentech, Inc., South San Francisco, CA
Purpose/Objective(s): MetMAb is a monovalent monoclonal antibody that
binds specifically to the Met receptor, blocking HGF-mediated activation. Met
expression is associated with worse prognosis in NSCLC, andMet activation has
been implicated in resistance to EGFR inhibition in EGFR-mutated NSCLC.
Dual inhibition of Met/EGFR may result in promising activity in NSCLC.
Materials/Methods: OAM4558g is a global randomized, double-blind phase II
study comparing MetMAb (15mg/kg IV q3wks) plus erlotinib (ME) to placebo
plus erlotinib (PE) in 2nd/3rd line NSCLC. Eligible patients on PE arm were
allowed to crossover to ME following progression. Patients were stratified by
histology, ECOG PS and smoking status. Archival tissue was mandatory for
determination of Met expression by IHC. Co-primary endpoints were PFS in the
Met high and ITT populations. Safety and OS were additional endpoints.
Results: 128 patients were randomized from 3/2009 to 3/2010 to ME (n64) or
PE (n64). Tissue was evaluable for Met in n121 and for EGFR and KRAS
mutations in n112. 23 patients crossed over toME, following progression from
PE. Baseline characteristics were well-balanced in the ITT population including
Met high (51%/57%; PE/ME) KRAS mutation (23%/23%) and EGFR mutation
(11%/13%). As of the June 8 data cut there were 85 PFS and 49 OS events. Both
a PFS benefit (HR 0.56; 95% CI 0.31, 1.02; p0.05,) and an OS benefit (HR
0.55; 95% CI 0.25, 1.16; p0.11) were observed in the Met high patients treated
with ME. However, in the Met low population, PFS (HR 2.01; 95% CI 1.04,
3.91; p0.04) and OS (HR 3.26; 95% CI 1.20, 8.80; p0.01) were worse in the
ME cohort. HR for PFS and OS in the ITT population were 1.09 (95% CI 0.71,
1.67; p0.70) and 1.13 (95% CI 0.64, 1.97; p0.68). Selective benefit of ME
was not observed in other subgroups, including: nonsquamous, EGFR or KRAS
mutants. Rash, diarrhea, and fatigue were comparable between treatment arms in
both Met high and Met- subpopulations. The incidence of Gr 3 AEs was
similar in ME v. PE in the Met high group (54% v. 53%); however, was higher
in the ME arm in the Met low group (52%vs 35%).
Conclusions: The addition of MetMAb to erlotinib in patients with Met high
NSCLC improved both PFS and OS and with no unexpected safety signal.
Conversely, Met low NSCLC patients had worse PFS and OS when treated
with ME, and a higher incidence of Gr 3 AEs. A prospective study of ME
v. PE in patients selected for Met high tumors is warranted.
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Sunitinib in Combination With Erlotinib for the Treatment of
Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC): a
Phase III Study
R. Govindan1, M. J. Krzakowski2, A. Szczesna3, J. Strausz4, A. N. Makh-
son5, M. Reck6, L. Tye7, K. Zhang7, R. C. Chao7, G. V. Scagliotti8,
1Washington University School of Medicine, St Louis, MO, 2The Maria
Sklodowska-Curie Memorial Cancer Center Institute of Oncology, Warsaw,
Poland, 3Regional Lung Diseases Hospital, Otwock, Poland, 4Koranyi Na-
tional Institute for Pulmonology, Budapest, Hungary, 5Moscow City Clinical
Hospital of Oncology #62, Moscow, Russian Federation, 6Hospital Gross-
hansdorf, Grosshansdorf, Germany, 7Pfizer Oncology, La Jolla, CA, 8Uni-
versity of Turin, Orbassano (Turin), Italy
Purpose/Objective(s): Angiogenesis and EGFR signaling pathways are
important in the pathogenesis of NSCLC. Sunitinib (SU) is an oral multi-
targeted tyrosine kinase inhibitor (TKI) of VEGFRs, PDGFRs, KIT and other
receptors. Preclinical data suggested SU  erlotinib (E), an EGFR TKI
approved in recurrent NSCLC, may enhance antitumor activity compared
with either agent alone. In early clinical studies SU  E was tolerable. This
phase III, multicenter, randomized, double-blind trial investigated overall
survival (OS) for SU  E vs. placebo (P)  E in patients (pts) with NSCLC
after failure of platinum-based chemotherapy.
Materials/Methods: Pts (18 yrs; ECOG PS 0 or 1, previously treated with
1 to 2 chemotherapy regimens) had recurrent NSCLC for which E was
indicated. Pts were randomized (1:1) to SU 37.5 mg/d E 150 mg/d, or P
E 150 mg/d, stratified by prior bevacizumab use, smoking history, and EGFR
expression. The primary endpoint was OS based on 734 events. Secondary
endpoints included progression-free survival (PFS), RECIST objective re-
sponse rate (ORR), safety, and patient-reported outcomes.
Results: 960 patients were randomized; baseline characteristics were bal-
anced and included adenocarcinoma (52.7%) and squamous cell carcinoma
(28.1%) histologies, median age was 61 yrs, 60.5% were male, and 19.4%
were never smokers. Median OS was 9.0 months for SU  E vs. 8.5 months
for P  E (HR [95%CI]: 0.922 [0.797-1.067]; p0.1388, 1-sided, stratified
log-rank). Median PFS was in favor of SU  E: 15.5 weeks vs. 8.7 weeks
for P  E (HR [95%CI]: 0.807 [0.695-0.937]; p0.0023, 1-sided, stratified
log-rank) and ORR was 10.6% vs. 6.9% (p0.0471, 2-sided), respectively.
Common treatment-related adverse events (Grade3) in both arms included
diarrhea, rash, decreased appetite, fatigue, and nausea.
Conclusions: This phase III trial in recurrent NSCLC did not demonstrate an
increase in OS but did demonstrate a significant improvement in PFS for
SU  E compared with P  E. Further efficacy and safety analyses will be
presented at the meeting.
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Subgroup Analysis of LUX-Lung 1: A Randomized Phase III
Trial of Afatinib (BIBW 2992)  Best Supportive Care (BSC)
versus Placebo BSC in Patients with NSCLC Failing 1-2 Lines
of Chemotherapy and Erlotinib or Gefitinib
V. A. Miller1, V. Hirsch2, J. Cadranel3, Y. Chen4, K. Park5, S. Kim6, R.
Lorence7, M. Shaidi8, J. Cong7, C. Yang9, 1Memorial Sloan Kettering
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Purpose/Objective(s): There is an unmet medical need for new systemic
therapies active in NSCLC patients after failure of chemotherapy and
reversible EGFR tyrosine kinase inhibitors (TKIs), erlotinib (E) or gefitinib
(G). Afatinib (A), is an irreversible TKI of EGFR & HER2 with preclinical
activity against EGFR T790M, a common mechanism of resistance in this
setting.
Materials/Methods: 585 adenocarcinoma patients [stage IIIB/IV, PS 0-2,
1-2 prior chemotherapies, progressed after 12 wks of E or G] were
randomized double-blind 2:1 to BSC  either oral A 50 mg qd or placebo
(P). The primary endpoint was OS (90% power to detect a 0.70 HR) with
secondary endpoints that included PFS, objective response rate (ORR), and
disease control rate (DCR).
Results: Patient characteristics [median age (58), women (60%), East Asian
(58%), PS 0-1 (92%)] were balanced across both arms. Successful clinical
enrichment for patients likely to have EGFR mutations was indicated by:
81% of patients with  24 wks of prior E/G and 45% with CR/PR on prior
E/G. At primary analysis (358 events), median OS was 10.8 mos with
BSC  A vs 12.0 mos with BSC  P, HR  1.08 (95% CI 0.86-1.35).
However, treatment with A lead to significant improvement in key secondary
efficacy endpoints: [1] PFS by independent review (3-fold increase in median
PFS from 1.1 to 3.3 mos, HR  0.38, P 0.0001, robust across all
preplanned subgroups); [2] confirmed DCR at 8 wks (58% vs 19%, P 
0.0001); & [3] confirmed ORR (11% vs 0.5% and 7.4% vs 0.5% by
investigator & independent analyses, P  0.01). Median PFS was improved
from 0.97 to 3.7 mos (HR 0.23, P  0.001) in the 263 pts who had CR/PR
to prior E/G. In the 214 patients with clinical benefit on prior E/G (CR/PR or
SD with treatment duration  6 months) AND short interval after prior E/G
and randomization ( 4 wks and no intervening chemotherapy), PFS
improvement for afatinib was as good if not better than the whole study
population: Median PFS of 4.5 mos for afatinib vs. 1.0 mos for placebo.
Since PFS in the placebo arm was very short and OS was long, possible
confounding effects of subsequent treatment on OS are being examined and
will be presented. Diarrhea (87% all grades; 17% gr 3) and rash/acne (78%
all gr; 14% gr 3) were the two most common side effects of A and effectively
managed by supportive care and dose modification.
Conclusions: In this phase III trial, the addition of afatinib to BSC did not
improve OS. Afatinib significantly improved PFS and was associated with a
higher ORR & DCR. Subgroup analysis suggests that the PFS benefit is
higher in patients likely to have EGFR mutations.
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A Phase II Trial of Sequential Versus Concurrent Chemother-
apy and Radiotherapy Using an Accelerated Hypofractionated
Radiation Schedule in Stage III NSCLC
J. Maguire1, R. McMenemin2, N. O’Rourke3, C. Peedell4, M. Snee5, S.
McNee3, V. Kelly1, 1Liverpool Heart and Chest Hospital, Liverpool, United
Kingdom, 2Northern Centre for Cancer Care, Newcastle, United Kingdom,
3The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom,
4James Cook University hospital, Middlesbrough, United Kingdom, 5St
James University Hospital, Leeds, United Kingdom
Purpose/Objective(s): Local tumour control and recurrence is a major
problem in the management of inoperable stage III NSCLC. A strategy to
avoid the detrimental effects of accelerated repopulation - administration of
a radical radiotherapy dose within a period of 28 days - might improve local
control rates and hence survival for this group of patients. To test this
hypothesis, we have conducted a randomised phase II trial in which patients
received a radiation dose of 55Gy in 20 fractions in four weeks, given either
sequentially after four cycles of cisplatinum and vinorelbine or concurrently
with the same chemotherapy.
Materials/Methods: 130 patients were randomised to receive 55Gy (pre-
scribed at the ICRU reference point) in 20 fractions over 4 weeks, with 4
cycles of cisplatinum and vinorelbine given either prior to RT or starting
concurrently with the first fraction of radiation. Trial entry required; patho-
logically confirmed stage III NSCLC judged inoperable by a thoracic
surgeon, and treatable within a radical RT volume with v20  30% and12
cms oesophagus in PTV; PS 0 or 1, FEV1  1L and TLCO  50%. The
protocol did not exclude patients with weight loss or N3 disease, and there
was no upwards age limit. Treatment was with either 3D conformal RT or 4D
(one centre). The required GTV - PTV margin was 1.5 cm for conformal and
1cm for 4D planning. Median age was 62 (range 39 - 77); 61% were male;
histology was 64% squamous, 27% adenoca; 52% were PS 0; 44% had IIIA
and 56% had IIIB disease. Patient characteristics were well balanced be-
tween the two arms.
Results: 67 patients received concurrent treatment and 60 sequential. This
report is at a median follow up of 25 months. The median number of
chemotherapy cycles was 3 in the concurrent arm (con) and four in the
sequential arm (seq). 53% vs 60% of patients had chemotherapy dose delays.
Incidence of Serious Adverse Events was 46% vs 47%. There were 43 grade
3 or 4 toxicities (29% vs 38%) - 15 were grade 4 (7 con, 8 seq). Six con
patients and one seq suffered CTC grade 3 oesophagitis. Grade 4 oesoph-
agitis did not occur. 49.3% of patients receiving concurrent treatment and
64.4% of sequential patients have died. Median survival was 27.6 months for
concurrent (projected) and 18.8 months for sequential treatment. Two year
survival is 54% for patients receiving 55Gy in 20 fractions with concurrent
cisplatinum and vinorelbine.
Conclusion: This is the first randomised trial in stage III NSCLC to achieve
a two year survival rate in excess of 50%. A strategy to minimise the effects
of accelerated repopulation using accelerated hypofractionated radiotherapy
with chemotherapy is effective for patients with stage III NSCLC.
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Use of a Continuous EGFR IHC Scoring Method Reveals Asso-
ciation between Tumor Response and EGFR Expression Levels
for Patients Receiving Cetuximab  CT versus CT Alone in the
Phase III Trial FLEX in Advanced NSCLC
K. O’Byrne1, W. E. E. Eberhardt2, S. Störkel3, K. Schumacher4, S. Heeger4,
C. Stroh4, I. Celik4, A. von Heydebreck4, R. Pirker5, 1St. James’s Hospital,
Dublin, Ireland, 2University Hospital Essen, University Duisberg-Essen,
Essen, Germany, 3Institute of Pathology der UWH, Helios Klinikum Wup-
pertal, Wuppertal, Germany, 4Merck KGaA, Darmstadt, Germany, 5Medical
University of Vienna, Vienna, Austria
Purpose/Objective(s): The FLEX phase III trial in advanced NSCLC
showed a statistically significant overall survival benefit for patients receiv-
ing cetuximab  CT versus CT alone (Pirker R et al. Lancet 2009, 373,
1525). Objective response rates were 36.4% in the cetuximab  CT arm
versus 29.2% in the CT alone arm. The objective of this study was to
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